Novus Flt-3/Flk-2/CD135 Antibody (BV10A4), 0.1 mg Item ID: NOVNBP142792

Flt-3/Flk-2/CD135 Antibody (BV10A4) Summary

Immunogen	BV-173 leukemic cell line
Specificity	The mouse monoclonal antibody BV10A4 (BV10) reacts with CD135 (FLT3, FLK2, STK-1), a 130-160 kDa type III receptor tyrosine kinase that is involved in early steps of hematopoiesis.
Isotype	IgG1
Clonality	Monoclonal
Host	Mouse
Gene	FLT3
Purity	Protein A purified
Innovator's Reward	Test in a species/application not listed above to receive a full credit towards a future purchase.Learn about the Innovator's Reward

Applications/Dilutions

Dilutions	Flow Cytometry 1:10-1:1000 Immunoprecipitation 1:50 CyTOF-ready
Application Notes	Flow Cytometry: Tested on cell lines K562 and REH. In this case the recommended concentration is 10 ug/ml per 1 million cells/ml.
Theoretical MW	160 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Reactivity Notes

Does not cross react with Mouse.

Packaging, Storage & Formulations

Storage	Store at 4C. Do not freeze.
Buffer	PBS (pH 7.4)
Preservative	15mM Sodium Azide
Concentration	1.0 mg/ml
Purity	Protein A purified

Alternate Names for Flt-3/Flk-2/CD135 Antibody (BV10A4)

• CD135 antigen
• CD135
• EC 2.7.10
• fetal liver kinase 2
• FL cytokine receptor
• FLK2
• Flk-2
• FLT3 receptor tyrosine kinase
• Flt3
• Flt-3
• Fms-like tyrosine kinase 3
• fms-related tyrosine kinase 3
• growth factor receptor tyrosine kinase type III
• Stem cell tyrosine kinase 1
• STK-1
• STK1EC 2.7.10.1
• Tyrosine-protein kinase receptor FLT3

Background

CD135 / FLT3, also known as FLK2 or STK-1 is a receptor tyrosine kinase that plays important roles in hematopoiesis. After binding of Flt3 ligand (FL), CD135 homodimerizes and stimulates proliferation, differentiation and protects the cell from apoptosis. The loss of CD90 and gain of CD135 expression marks the loss of self-renewal in hematopoietic stem cell population. Detectable CD135 expression appears first at low levels on the surface of primitive multilineage progenitor cells and disappears during defined stages of B-cell development, but is upregulated and maintained during maturation of monocytes. CD135 is also expressed on thymocytes, dendritic cell progenitors and on mature dendritic cells, as well as on various malignant hematopoietic cells.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.